TP53-mutated AML is also enriched for the tumor inflammation signature (TIS), as well as characterized by the upregulation of immune checkpoints such as PD-L1, TIGIT, and LAG3 and markers of immune senescence [77]. Here, TP53 is linked to neoplasm.